Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.09.2014 | review article | Ausgabe 17-18/2014 Open Access

Wiener klinische Wochenschrift 17-18/2014

Dabigatran: patient management in specific clinical settings

Wiener klinische Wochenschrift > Ausgabe 17-18/2014
MD Paul Alexander Kyrle, MD Konrad Binder, MD Sabine Eichinger, MD Reinhold Függer, MD Bernd Gollackner, MD J. Michael Hiesmayr, MD Kurt Huber, MD Wielfried Lang, MD Peter Perger, MD Peter Quehenberger, MD Franz X. Roithinger, MD Sabine Schmaldienst, MD Ansgar Weltermann, MD Hans Domanovits


Dabigatran, a direct thrombin inhibitor, is licensed for the prevention of venous thromboembolism after knee and hip replacement, the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for the treatment of acute venous thromboembolism. As dabigatran has a favourable benefit–risk profile, it is being increasingly used. Dabigatran differs from vitamin K antagonists as regards its pharmacological characteristics and its impact on certain laboratory tests, and also in the lack of a direct antagonist that can reverse dabigatran-induced anticoagulation. In emergency settings such as acute bleeding, emergency surgery, acute coronary syndrome, thrombolysis for ischaemic stroke or overdosing, specific strategies are required. A working group of experts from various disciplines has developed strategies for the management of dabigatran-treated patients in emergency settings.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 17-18/2014

Wiener klinische Wochenschrift 17-18/2014 Zur Ausgabe

gesellschaft der ärzte in wien

Billrothhaus September